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Screening of newborn infants for Cystic Fibrosis (CF NBS), one of the most
common monogenic diseases among Caucasians, has already been introduced in
many countries. One of the most frequent CF symptoms is malnutrition, which can
easily be overcome after rapid diagnosis. Due to healthcare system organization
in Poland prompt specialists availability is rather difﬁcult resulting in late CF
diagnosis. Therefore CF NBS seems to be here of additional advantage.
CF NBS covers 8 Polish regions and is organized according to current guidelines
including IRT determination in dried blood spots, identiﬁcation of the CFTR gene
mutations and sweat chloride test. Our strategy of molecular analysis is based on
sequencing of ﬁve CFTR exons (7, 10, 11, 13, 21). This allows to identify 15
most frequent mutations in Poland and about 300 rare variants. Analysis based on
commercial tests (INNOLiPA 12/19/17+Tn, Innogenetics; OLA Assay v3, Abbott)
does not seem to be sensitive enough as only about 50% of mutations covered by
them have ever been identiﬁed in Polish population.
CF NBS was started in September 2006. Until December 2007, 1005 samples,
selected on the basis of IRT level over cut-off, underwent DNA analysis. Molec-
ular conﬁrmation of CF diagnosis was achieved in 30 patients with genotypes
*F508del/F508del (15 cases), *F508del/other mutation (7), *other mutation/other
mutation (8).
In 3 patients with CF conﬁrmed clinically only 1 mutation (F508del) was identiﬁed.
The frequency of F508del among CF alleles in tested population was evaluated as
60.6%.
We also identiﬁed 80 symptomless carriers. Their follow-up observation is neces-
sary. Further study will result in recognition of CF epidemiology and heterogeneity
of CFTR mutations in Poland.
